Sanaria received the 2014 Vaccine Industry Excellence Award for the “Best Prophylactic Vaccine” at a ceremony held March 25 in Washington DC during the 14th World Vaccine Congress. Vaccines from Sanofi Pasteur, GSK, and Novartis were among the 6 finalists competing with Sanaria. The awardee, Sanaria® PfSPZ Vaccine, demonstrated complete protection against malaria in all volunteers (6/6) who received high dose immunizations in a trial at the Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), NIH. The clinical trial results were published online in Science magazine in August 2013.
Additional safety, efficacy and regimen refinement studies are underway led by teams from the VRC, NIAID, NIH and the University of Maryland School of Medicine in the US, and from the University of Bamako and the Laboratory of Malaria Immunology and Vaccinology (LMIV), NIAID, in Mali. Trials of PfSPZ Vaccine are also planned to begin in the next few months at the Ifakara Health Institute, Tanzania, the Naval Medical Research Center and Walter Reed Army Institute of Research, USA, Ministry of Health, Equatorial Guinea, and the University of Tübingen, Germany. Sanaria has pioneered the manufacture, storage, shipping, and administration of Plasmodium falciparum sporozoite stage malaria parasites as vaccines. With collaborating partners in the US, Europe, and Africa, Sanaria is optimizing vaccine dosage regimens and performance characteristics and establishing operational systems for mass administration of PfSPZ Vaccine to be used in malaria elimination campaigns.
“We are extremely honored by this award, which represents the recognition of our industry peers,” said Stephen L. Hoffman, MD, President and founder of Sanaria, who was also among the 6 finalists for this year’s ViE “Best Biotech CEO” award. Ogobara Doumbo, MD, PhD, Director of the Malaria Research and Training Centre of the University of Bamako, Mali, said, “This announcement is a great boost for our staff and volunteers, collaborating with LMIV, NIAID and Sanaria to test the PfSPZ Vaccine in the field here inMali. The months ahead are going to be very exciting for us, and hopefully for everyone working in malaria.” Salim Abdulla, MD, PhD, Director of the Ifakara Health Institute, Tanzania, the first organization in Africa to conduct clinical trials of a PfSPZ product, and the site of an upcoming trial of PfSPZ Vaccine, said, “This industry recognition communicates to all of our colleagues in Tanzania why we and our colleagues and supporters at the Swiss Tropical and Public Health Institute have committed so much of our resources and time to assessing PfSPZ Vaccine, and our vision to use it as a tool to eliminate P. falciparum malaria.”
The Vaccine Industry Excellence Awards honor the global vaccine industry’s outstanding achievements. Experts drawn from the pharmaceutical and biotech industries, pharmaceutical consultants, public health organizations, NGOs, and academic and research institutions judge the award nominees. These experts provide unprecedented combined knowledge of the status of contemporary vaccine development efforts.
About Sanaria Inc.:
Sanaria Inc. was founded in 2003. The Company’s mission is to develop and commercialize whole-parasite malaria vaccines that confer high-level, long-lasting protection against Plasmodium falciparum, the parasite responsible for most of the malaria-associated severe illness and death worldwide, and the other parasites that cause human malaria, and to use these vaccines to eliminate malaria. Sanaria’s corporate headquarters, administrative, research, development, and manufacturing operations are located inRockville, Maryland. The Company’s website is http://www.sanaria.com.
Except for historical information, this news release contains certain forward-looking statements that involve known and unknown risk and uncertainties, which may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the statements made. Such statements include the availability of an effective vaccine, the expectations for conquering malaria, beliefs concerning the suitability of a successful vaccine, and the establishment of a path toward prevention of infection. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the Company’s ability to raise sufficient funds, the regulatory approval process, dependence on third parties, clinical trials results, the Company’s patent portfolio, ability to commercialize the vaccine, dependence on key personnel and other risks associated with vaccine development. For further information contact Adam Richman, firstname.lastname@example.org, 240-403-2726.